Year results
With the financial year 2010 ended, it is time to take stock of what happened in the last 12 months, from both the economical and strategic point of view.
2010 has been a tough year, marked by a profound international crisis, and we had to overcome the very good results obtained in 2009 due to pandemic influenza. In 2010 we have maintained a moderate growth of 6% over the previous year, but which represents 26% if we discount the ‘pandemic effect’. The international contribution to total sales has remained at the rate of 64%.
The introduction of our product Pneumoslide IgM, SFDA approved, in the Chinese market, has meant an important milestone for our company. This year we have adapted our production capacity to meet the demand of the second largest IVD market in the world. Several visits and product training have taken place in collaboration with our exclusive Chinese distributor Autobio Co. Ltd.
Our presence in Asia has increased significantly in 2010; however Europe, LATAM and Middle East remain as our most important natural markets. Moreover, in 2010 the proportion of sales of our business lines remain similar to 2009, marked only by the increase in IFA, Rapid tests and ELISA to the detriment of sales of transport media.
In 2010 our product portfolio went up with the launch of new references in ELISA, rapid tests, Speed-oligo® and PCR controls, and we have increased our presence in the countries of Eastern Europe.
Among our strategic objectives for 2011 are the reinforcement of our penetration in the BRIC countries (Brazil, Russia, India and China), the construction of new facilities and the launching of new products as result of our efforts in R&D.